secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001213900-25-108847
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q3 net loss $6.0M, cash $42.7M; plans OLC NDA resubmission by year-end 2025
--------------------------------------------------------------------------------

- Net loss of $6.0M for Q3 2025 vs $4.1M in Q3 2024; cash $42.7M as of Sept 30, 2025, with runway into 2027.
- On track to resubmit NDA for oxylanthanum carbonate (OLC) by year-end 2025 after positive FDA Type A meeting; potential PDUFA in H1 2026.
- Presented OLC data at ASN Kidney Week showing 7x reduction in pill volume and 2x reduction in pill count vs current binders.
- R&D expenses flat at $3.0M; G&A increased to $4.4M from $3.2M due to higher labor and consulting costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/0001213900-25-108847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/ea0265227-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer